WX390

DRUG4 trials

Sponsors

Shanghai Jiatan Pharmatech Co., Ltd

Conditions

Gastric Type Adenocarcinoma (GAS) With STK11 MutationPIK3CA Mutation-Related TumorsSolid Tumor

Phase 1

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

RecruitingNCT06117566

Shanghai Jiatan Pharmatech Co., LtdSolid Tumor

Start: 2022-11-18End: 2025-11-09Target: 100Updated: 2024-11-25

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

CompletedNCT06132932

Shanghai Jiatan Pharmatech Co., LtdPIK3CA Mutation-Related Tumors

Start: 2021-06-03End: 2023-01-03Updated: 2023-11-15

Phase 2

A Study of WX390 in Patients With Advanced Solid Tumors

RecruitingNCT06117540

Shanghai Jiatan Pharmatech Co., LtdSolid Tumor

Start: 2021-05-11End: 2026-06-12Target: 70Updated: 2024-11-19

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

RecruitingNCT06124963

Shanghai Jiatan Pharmatech Co., LtdGastric Type Adenocarcinoma (GAS) With STK11 Mutation

Start: 2023-08-25End: 2026-12-09Target: 20Updated: 2024-12-10

Related Papers

Abstract CT029: Preliminary outcomes from a phase 1b/2 study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer

Cancer Research2025-04-25

Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy.

2025-04-141 citations

Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-013 citations